Form 4: Y-mAbs Therapeutics Director Mary Tagliaferri Reports Stock and Option Grants

Director Mary Tagliaferri reports receiving restricted stock units and stock options from Y-mAbs Therapeutics.

Summary

• On June 11, 2024, Mary Tagliaferri, a director of Y-mAbs Therapeutics, reported transactions involving the company's securities.
• Tagliaferri was granted 3,495 restricted stock units (RSUs) and 14,545 stock options under the company's 2018 Equity Incentive Plan.
• The RSUs vest on the earlier of the first anniversary of the grant date or the date immediately preceding the 2025 annual meeting, contingent upon continued service.
• The stock options vest in equal monthly installments over one year from the grant date and are exercisable immediately upon vesting.
• The exercise price of the stock options is $12.01.
• Following these transactions, Tagliaferri beneficially owns 8,155 shares of common stock and 14,545 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports standard equity grants to a director, which is a common practice. There are no explicit positive or negative implications.

Positives

• The grant of RSUs and stock options aligns Tagliaferri's interests with those of the shareholders.
• The vesting schedules incentivize continued service to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the granted securities.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates compensation and alignment of interests between the director and the company's performance.

Comparison to Industry Standards

• Equity grants are a common form of compensation for directors and executives in the biotechnology industry.
• Vesting schedules are typically structured to incentivize long-term commitment and performance, aligning with industry norms.
• The specific terms of the grants (number of shares, exercise price, vesting schedule) would need to be compared to peer companies to assess their competitiveness.

Stakeholder Impact

• The grant of equity to a director can align their interests with those of shareholders, potentially leading to better decision-making.
• Employees may view the equity grants as a positive sign of the company's commitment to its leadership.

Key Dates